Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and pembrolizumab in advanced angiosarcoma and undifferentiated pleomorphic sarcoma
2021-003788-82Phase 2Active
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol and pembrolizumab in angiosarcoma and Malignant Fibrous Histiocytoma (MFH), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Progression-free survival rate at 3 months. Started Jul 2021; status: active.
02
Drugs
propranololpembrolizumab
03
Conditions
angiosarcomaMalignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on 2021-003788-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003788-82.